At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Rucaparib +1 moredrug
Likely dose
Rucaparib 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
In Brief
A Phase 2 clinical trial evaluating Rucaparib and Bevacizumab for Cervical Cancer and Endometrial Cancer. Completed, enrolled 49 participants across 3 sites.
Detailed Summary
This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer, Endometrial Cancer
CountriesUnited States
CollaboratorsClovis Oncology, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartJun 2018
Primary CompletionMay 2020
Study CompletionSep 2023
TodayJul 2026
First PostedMar 26, 2018
Enrollment StartJun 29, 2018
Primary CompletionMay 12, 2020
Study CompletionSep 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.3 years ago
Interventions
Rucaparibdrug
Rucaparib 600mg PO BID daily
Bevacizumabdrug
Bevacizumab 15mg/kg IV on day 1 of each cycle